A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients
Journal Title: The AAPS Journal - Year 2015, Vol 17, Issue 6
Abstract
The online version of this article (doi:10.1208/s12248-015-9815-8) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Ahmed Abbas Suleiman, Sebastian Frechen, Matthias Scheffler, Thomas Zander, Lucia Nogova, Martin Kocher, Ulrich Jaehde, Jürgen Wolf, Uwe Fuhr
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
The development of therapeutic proteins requires the understanding of the relationship between the dose, exposure, efficacy, and toxicity of these molecules. Several intrinsic and extrinsic factors contribute to the chal...
Erratum to: Generic Development of Topical Dermatologic Products: Formulation Development, Process Development, and Testing of Topical Dermatologic Products
The online version of the original article can be found at 10.1208/s12248-012-9411-0.
Poly(butylcyanoacrylate) and Poly(ε-caprolactone) Nanoparticles Loaded with 5-Fluorouracil Increase the Cytotoxic Effect of the Drug in Experimental Colon Cancer
The clinical use of 5-fluorouracil, one of the drugs of choice in colon cancer therapy, is limited by a nonuniform oral absorption, a short plasma half-life, and by the development of drug resistances by malignant cells....
Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice
Drug treatment poses a therapeutic challenge in cystic fibrosis (CF) because the disposition of a number of drugs is altered in CF. Enhanced clearance of acetaminophen (APAP) and indocyanine green (ICG) have previously b...
Statistical Power Calculations for Mixed Pharmacokinetic Study Designs Using a Population Approach
Simultaneous modelling of dense and sparse pharmacokinetic data is possible with a population approach. To determine the number of individuals required to detect the effect of a covariate, simulation-based power calculat...